Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) is increasingly used for the staging of solid malignancies, including lung and esophagus. However, controversy still exists in relation to the application of PET in pancreatic cancer. The authors review seven studies (Abstracts #183, #189, #190, #254, #357, #375, #378) presented at the 2014 ASCO Gastrointestinal Cancers Symposium and discuss on the role of PET in this disease.
View Article and Find Full Text PDFPancreatic cancer is the fourth leading cause of cancer deaths. Since the majority of patients present with incurable metastatic disease, novel imaging methods are needed to identify pancreatic cancer and assess response to therapy. Research presented at the 2013 American Society of Oncology (ASCO) Annual Meeting provided insight into potential imaging methods.
View Article and Find Full Text PDF